Drug

Pharmacologic Class

Indication

More Information

Dermatological Disorders
NexoBrid (anacaulase-bcdb) Topically administered, bromelain-based biologic Treatment for eschar removal in adults with deep partial thickness and/or full thickness thermal burns. Severe Burn Therapy NexoBrid Gets FDA Approval
Diagnostic Agents
Cytalux (pafolacianine) Fluorescent drug that binds to folate receptor-expressing cancer cells To identify malignant and nonmalignant pulmonary lesions in adults with known or suspected lung cancer, in addition to detecting ovarian cancer lesions. Cytalux Approval Expanded to Include Lung Cancer Detection During Surgery
Xenoview (xenon Xe 129 hyperpolarized) Hyperpolarized contrast agent For use with magnetic resonance imaging for evaluation of lung ventilation in adults and pediatric patients 12 years of age and older. FDA Approves Xenoview for Evaluating Lung Ventilation
Infectious Disease
Actemra (tocilizumab)   Interleukin-6 antagonist Treatment of COVID-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. Actemra Drug Monograph
Sunlenca (lenacapavir) HIV-1 capsid inhibitor In combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Sunlenca Approved for Patients With Multidrug-Resistant HIV-1 Infection
Metabolic Disorders
Olpruva (sodium phenylbutyrate) Nitrogen-binding agent Treatment of patients with urea cycle disorders. Olpruva Approved for Patients With Urea Cycle Disorders
Musculoskeletal Disorders
Tymlos (abaloparatide) A human parathyroid hormone related peptide analog To increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. Tymlos Approved for Men With Osteoporosis at High Risk for Fracture
Neurologic Disorders
Briumvi (ublituximab-xiiy) A glycoengineered monoclonal antibody that targets CD20 Treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Briumvi Approved for Relapsing Forms of Multiple Sclerosis
Obstetrics and Gynecology
Brexafemme (ibrexafungerp) Triterpenoid antifungal For the reduction in the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal pediatric females. Brexafemme Drug Monograph
Oncology
Rezlidhia (olutasidenib) Isocitrate dehydrogenase-1 inhibitor. For the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test. Rezlidhia Drug Monograph
Tecentriq (atezolizumab) Programmed death-ligand 1 blocking antibody For the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma. Tecentriq Drug Monograph
Krazati (adagrasib) RAS GTPase (family) inhibitor For the treatment of adults with KRASG12C-mutation locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least 1 prior systemic therapy. Krazati Drug Monograph
Adstiladrin (nadofaragene firadenovec-vncg) Nonreplicating adenoviral vector-based gene therapy For the treatment of adults with high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Gene Therapy Approved for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Lunsumio (mosunetuzumab-axgb) CD20xCD3 T-cell engaging bispecific antibody Treatment of adults with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy. Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Ophthalmic Disorders
Iyuzeh (latanoprost ophthalmic solution) Prostaglandin F2α analogue For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Iyuzeh Approved for Patients With Open-Angle Glaucoma, Ocular Hypertension
Psychological Disorders
Vraylar (cariprazine) Atypical antipsychotic An adjunctive therapy to antidepressants for the treatment of major depressive disorder. Vraylar Drug Monograph